The European Medicines Agency (EMA) has started the process of rolling review of the new version of the Pfizer vaccine, Comirnaty, adapted for the specific subvariants of omicron, a previous step to be approved.
The European regulator has given free rein to the rolling review for this new Pfizer vaccine, an exceptional mechanism approved during the pandemic so that regulatory agencies can evaluate clinical data as they are generated to